SAN DIEGO and SHANGHAI, China and HONG KONG, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) announce today that the first participant, based in the United States, was dosed in a global Phase I trial of IMG-004, a non-covalent, reversible, third-generation Bruton Tyrosine Kinase (“BTK”) inhibitor. Inmagene is developing the drug candidate to potentially treat immunological diseases. The Phase I study
— MET is the most common biomarker in patients with EGFR-mutated lung cancer who develop resistance to targeted therapy — — Global SAFFRON Phase III trial evaluating this combination is underway — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) and AstraZeneca PLC (“AstraZeneca”) (LON/STO/Nasdaq: AZN) today announce that preliminary results from the SAVANNAH Phase II trial showed that TAGRIS
— Trial met primary endpoint of overall survival and all secondary endpoints — — Overall safety consistent with fruquintinib known profile — — Plans for regulatory submissions underway in the U.S., Europe and Japan — — Results to be submitted to an upcoming medical meeting — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J.,, Aug. 07, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) today announces that the pivotal global Phase 3 FRESCO-2 trial evalua